Clinical Trials

With $82M in funding and novel gene insertion technology, Averna Therapeutics is poised to make waves at the pivotal J.P. Morgan Healthcare Conference.

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.

With blockbuster preliminary sales and rapid patient adoption, Liquidia's new inhaled therapy is challenging established players in the lung disease space.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

After success in Europe, Allotex gets FDA nod to begin U.S. trials for its tissue-based presbyopia treatment, offering new hope for millions.

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

As it marks 32 years, Alexandria Real Estate Equities proves its resilience, dominating the market it created amid industry-wide headwinds.

Hoth Therapeutics files patents for a therapy to mitigate severe skin reactions from cancer treatments, a strategic move that could transform patient care.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

The neuro-focused biotech just acquired a late-stage cancer drug, securing massive funding. Is this a brilliant diversification or a high-stakes gamble?

A Phase 1 trial for Moleculin's WP1066 shows encouraging safety and anti-tumor activity for children with deadly brain tumors like DIPG.

A new study reveals a tissue allograft, AmchoPlast™, triples healing rates for diabetic foot ulcers, offering a major breakthrough for a common complication.

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

With FDA alignment for its pivotal Phase 3 trial, Oncolytics Biotech is poised to bring the first immunotherapy to the challenging pancreatic cancer landscape.